Monica Else
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Monica Else has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Catovsky
Division of Molecular Pathology, The Institute of Cancer Research, London, UK
2 shared publications - Alan Ashworth
The Institute of Cancer Research, London, United Kingdom
1 shared publication - Alan Mackay
Division of Molecular Pathology, the Institute of Cancer Research, London SW7 3RP, UK
1 shared publication Chris Jones
Section of Paediatric Oncology, The Institute of Cancer Research (ICR), Sutton, Surrey, London, UK
1 shared publication- Claire Dearden
Department of Haemato-Oncology, Royal Marsden Biomedical Research Centre, London, UK
1 shared publication - Claire Dearden
St. George's Hospital Medical School, London, UK
1 shared publication
Latest Publications
- Open Access
- 1 December 2015
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 28 (4) , 217-229
Long-term follow-up after purine analogue therapy in hairy cell leukaemia
- 1 December 2015
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 28 (4) , 217-229
Open AccessLong-term follow-up after purine analogue therapy in hairy cell leukaemia
- 1 January 2008
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (10) , 1879-1886
Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescencein situhybridisation and array-based comparative genomic hybridisation
Deletion of the TP53 gene on chromosome 17p13.1 is the prognostic factor associated with the shortest survival in CLL. We used array-based comparative genomic hybridisation (arrayCGH) to identify additional DNA copy number changes in peripheral blood samples from 74 LRF CLL4 trial patients, 37 with ≥5% and 37 without TP53-deleted cells. ArrayCGH reliably detected deletions on 17p, including the TP53 locus, in cases with ≥50%TP53-deleted cells detected by fluorescence in situ hybridisation, plus seven additional cases with deleted regions on 17p excluding TP53. Losses on chromosomal regions 18p and/or 20p were found exclusively in cases with ≥5%TP53-deleted cells (p < 0.001), 38% having one or both losses. The incidence of additional cytogenetic abnormalities, reflecting an increased chromosomal instability, was higher in ≥5%TP53-deleted cases (p = 0.02). In particular, amplification of 2p and deletion of 6q were both more frequent. Cases with >20%TP53-deleted cells had the worst prognosis in the LRF CLL4 trial.
- 1 January 2008
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (10) , 1879-1886
Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescencein situhybridisation and array-based comparative genomic hybridisation
Deletion of the TP53 gene on chromosome 17p13.1 is the prognostic factor associated with the shortest survival in CLL. We used array-based comparative genomic hybridisation (arrayCGH) to identify additional DNA copy number changes in peripheral blood samples from 74 LRF CLL4 trial patients, 37 with ≥5% and 37 without TP53-deleted cells. ArrayCGH reliably detected deletions on 17p, including the TP53 locus, in cases with ≥50%TP53-deleted cells detected by fluorescence in situ hybridisation, plus seven additional cases with deleted regions on 17p excluding TP53. Losses on chromosomal regions 18p and/or 20p were found exclusively in cases with ≥5%TP53-deleted cells (p < 0.001), 38% having one or both losses. The incidence of additional cytogenetic abnormalities, reflecting an increased chromosomal instability, was higher in ≥5%TP53-deleted cases (p = 0.02). In particular, amplification of 2p and deletion of 6q were both more frequent. Cases with >20%TP53-deleted cells had the worst prognosis in the LRF CLL4 trial.